Focused On-demand Library for ATPase family gene 2 protein homolog B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BVQ7

UPID:

AFG2B_HUMAN

Alternative names:

AFG2 AAA ATPase homolog B; Ribosome biogenesis protein SPATA5L1; Spermatogenesis-associated protein 5-like protein 1

Alternative UPACC:

Q9BVQ7; C9JHR5; Q9H8W7; Q9HA41

Background:

ATPase family gene 2 protein homolog B, also known as AFG2 AAA ATPase homolog B, Ribosome biogenesis protein SPATA5L1, and Spermatogenesis-associated protein 5-like protein 1, is pivotal in the cytoplasmic maturation of pre-60S ribosomal particles. It facilitates the release of RSL24D1/RLP24, working alongside AFG2A, AIRIM, and CINP.

Therapeutic significance:

Linked to Deafness, autosomal recessive, 119, and Neurodevelopmental disorder with hearing loss and spasticity, understanding ATPase family gene 2 protein homolog B's role could unveil new therapeutic strategies.